This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Randomized Trial Comparing the Hepatic Artery With the Portal Vein

John M. Daly, MD; Nancy Kemeny, MD; Elin Sigurdson, MD, PhD; Paula Oderman, RN; Arleen Thom, MD

Arch Surg. 1987;122(11):1273-1277.

Abstract
• To evaluate which site of infusion maximizes tumor response to regional hepatic chemotherapy, 25 patients were randomized preoperatively to receive chemotherapy administration via hepatic artery or portal vein catheters. Of the 25 patients, five did not have catheters placed due to extrahepatic disease, and one patient did not receive infusion chemotherapy. Continuous floxuridine infusion was given at a dosage of 0.3 mg/kg/d, alternating with saline solution every two weeks. The mean percentage of hepatic tumor replacement (36% vs 41%), mean serum alkaline phosphatase level (218 vs 179 IU/mL), and mean plasma carcinoembryonic antigen level (689 vs 563 ng/mL) were similar in both groups. Four (50%) of eight hepatic artery patients responded to treatment compared with 0/11 portal vein patients. Ten of 11 portal vein patients showed progressive tumor growth; nine of these patients were crossed over to arterial infusion. Three (33%) of these nine patients had an objective tumor response with the hepatic arterial infusion. This prospective, randomized clinical trial demonstrates significantly improved tumor response after hepatic arterial infusion compared with portal vein infusion.

(Arch Surg 1987;122:1273-1277)

Author Affiliations
From the Departments of Surgery (Drs Daly, Sigurdson, and Thom) and Medicine (Dr Kemeny and Ms Oderman), Memorial Sloan-Kettering Cancer Center, New York.

Footnotes
Accepted for publication July 14, 1987.

Read before the Annual Meeting of the Society of Surgical Oncology, London, April 30, 1987.

Reprint requests to University of Pennsylvania School of Medicine, 3400 Spruce St, Philadelphia, PA 19104 (Dr Daly).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The role of floxuridine in metastatic liver disease
Power and Kemeny
Molecular Cancer Therapeutics 2009;8:1015-1025.
ABSTRACT | FULL TEXT  

Isolated Hypoxic Hepatic Perfusion with Retrograde Outflow in Patients with Irresectable Liver Metastases; A New Simplified Technique in Isolated Hepatic Perfusion
Verhoef et al.
Ann. Surg. Oncol. 2008;15:1367-1374.
ABSTRACT | FULL TEXT  

Improved Hepatic Toxicity Profile of Portal Vein Adjuvant Hepatic Infusional Chemotherapy
Faynsod et al.
JCO 2005;23:4876-4880.
ABSTRACT | FULL TEXT